Projecting Market Access Success For Early-Stage Pharma Assets: Getting Past The Hurdles

19 Feb 2013

All too often, pharmaceutical companies and investors put up hurdles, but they can and must identify indications and assets with high future market access potential in early stages by adjusting the early screening and evaluation process.

Commercial success of innovative pharmaceutical assets is increasingly driven by their market access position, which plays a key role in defining both the target population and pricing. As a result, the evaluation of future market access position should be an important criterion in the early identification and screening of assets by external investors or for allocation of internal research resources. (SeeAlso see "A Call For Action: Pharma Strategies For Development Of Payor Evidence Programs" - In Vivo, 24 February, 2012..)

Unfortunately, a critical analysis of investment approaches to products in early-stage development shows that future market access position often falls...